Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study
- 31 January 2007
- journal article
- research article
- Published by Elsevier in Fertility and Sterility
- Vol. 87 (1) , 202-206
- https://doi.org/10.1016/j.fertnstert.2006.05.061
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetesAtherosclerosis, 2006
- Abnormal aminotransferase activity in women with polycystic ovary syndromeFertility and Sterility, 2005
- Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivityFertility and Sterility, 2004
- Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndromeFertility and Sterility, 2004
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndromePublished by Elsevier ,2004
- Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the Ppar–γ Ligand RosiglitazoneHepatology, 2003
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Chronic Subclinical Inflammation as Part of the Insulin Resistance SyndromeCirculation, 2000
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in WomenNew England Journal of Medicine, 2000
- Cardiovascular Risk in Women With Polycystic Ovarian SyndromeSeminars in Reproductive Medicine, 1996